Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

OGI vs TLRY vs CGC vs CRON vs ACB

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
OGI
Organigram Global Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CA
Market Cap$186M
5Y Perf.-80.2%
TLRY
Tilray Brands, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CA
Market Cap$660M
5Y Perf.-42.5%
CGC
Canopy Growth Corporation

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CA
Market Cap$122M
5Y Perf.-99.3%
CRON
Cronos Group Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CA
Market Cap$981M
5Y Perf.-60.6%
ACB
Aurora Cannabis Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CA
Market Cap$195M
5Y Perf.-97.6%

OGI vs TLRY vs CGC vs CRON vs ACB — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
OGI logoOGI
TLRY logoTLRY
CGC logoCGC
CRON logoCRON
ACB logoACB
IndustryDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & Generic
Market Cap$186M$660M$122M$981M$195M
Revenue (TTM)$280M$1.17B$294M$193M$361M
Net Income (TTM)$18M$-2.95B$-327M$-9M$41M
Gross Margin28.9%28.0%22.8%32.5%62.7%
Operating Margin-10.2%-266.0%-24.1%-1.5%13.3%
Forward P/E9.8x34.3x164.2x
Total Debt$9M$451M$348M$2M$104M
Cash & Equiv.$28M$304M$114M$792M$184M

OGI vs TLRY vs CGC vs CRON vs ACBLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

OGI
TLRY
CGC
CRON
ACB
StockMay 20May 26Return
Organigram Global I… (OGI)10019.8-80.2%
Tilray Brands, Inc. (TLRY)10057.5-42.5%
Canopy Growth Corpo… (CGC)1000.7-99.3%
Cronos Group Inc. (CRON)10039.4-60.6%
Aurora Cannabis Inc. (ACB)1002.4-97.6%

Price return only. Dividends and distributions are not included.

Quick Verdict: OGI vs TLRY vs CGC vs CRON vs ACB

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: CRON and ACB are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. Aurora Cannabis Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. OGI and TLRY also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
OGI
Organigram Global Inc.
The Value Play

OGI ranks third and is worth considering specifically for value.

  • Lower P/E (9.8x vs 164.2x)
Best for: value
TLRY
Tilray Brands, Inc.
The Momentum Pick

TLRY is the clearest fit if your priority is momentum.

  • +12.1% vs ACB's -25.3%
Best for: momentum
CGC
Canopy Growth Corporation
The Healthcare Pick

Among these 5 stocks, CGC doesn't own a clear edge in any measured category.

Best for: healthcare exposure
CRON
Cronos Group Inc.
The Income Pick

CRON has the current edge in this matchup, primarily because of its strength in income & stability and long-term compounding.

  • beta 0.98
  • 14.6% 10Y total return vs TLRY's -74.7%
  • Lower volatility, beta 0.98, Low D/E 0.1%, current ratio 19.59x
  • Beta 0.98, current ratio 19.59x
Best for: income & stability and long-term compounding
ACB
Aurora Cannabis Inc.
The Growth Play

ACB is the #2 pick in this set and the best alternative if growth exposure is your priority.

  • Rev growth 27.0%, EPS growth 102.2%, 3Y rev CAGR 15.8%
  • 11.2% margin vs TLRY's -252.6%
  • 5.2% ROA vs TLRY's -100.6%, ROIC 0.7% vs -66.2%
Best for: growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthCRON logoCRON64.4% revenue growth vs CGC's -9.5%
ValueOGI logoOGILower P/E (9.8x vs 164.2x)
Quality / MarginsACB logoACB11.2% margin vs TLRY's -252.6%
Stability / SafetyCRON logoCRONBeta 0.98 vs TLRY's 2.03, lower leverage
DividendsTieNone of these 5 stocks pay a meaningful dividend
Momentum (1Y)TLRY logoTLRY+12.1% vs ACB's -25.3%
Efficiency (ROA)ACB logoACB5.2% ROA vs TLRY's -100.6%, ROIC 0.7% vs -66.2%

OGI vs TLRY vs CGC vs CRON vs ACB — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

OGIOrganigram Global Inc.
FY 2025
International Business To Business
68.9%$26M
Wholesale To Licensed Producers Revenue
24.5%$9M
Direct To Patient Medical Revenue
6.3%$2M
Other Revenue
0.4%$142,000
TLRYTilray Brands, Inc.
FY 2025
Cannabis Segment
36.1%$331M
Distribution Revenue
29.6%$271M
Beverage Alcohol Business
27.7%$253M
Wellness Business
6.6%$60M
CGCCanopy Growth Corporation
FY 2024
Canadian Cannabis Net Revenue
57.9%$156M
Storz And Bickel
27.3%$73M
International And Other Revenue
14.8%$40M
Other Revenue
0.0%$0
CRONCronos Group Inc.
FY 2025
Cannabis Flower
74.0%$108M
Cannabis Extracts
25.7%$38M
Product and Service, Other
0.3%$411,000
ACBAurora Cannabis Inc.

Segment breakdown not available.

OGI vs TLRY vs CGC vs CRON vs ACB — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLACBLAGGINGCGC

Income & Cash Flow (Last 12 Months)

ACB leads this category, winning 3 of 6 comparable metrics.

TLRY is the larger business by revenue, generating $1.2B annually — 6.0x CRON's $193M. ACB is the more profitable business, keeping 11.2% of every revenue dollar as net income compared to TLRY's -2.5%.

MetricOGI logoOGIOrganigram Global…TLRY logoTLRYTilray Brands, In…CGC logoCGCCanopy Growth Cor…CRON logoCRONCronos Group Inc.ACB logoACBAurora Cannabis I…
RevenueTrailing 12 months$280M$1.2B$294M$193M$361M
EBITDAEarnings before interest/tax-$9M-$3.0B-$32M-$810,000$71M
Net IncomeAfter-tax profit$18M-$2.9B-$327M-$9M$41M
Free Cash FlowCash after capex-$36M-$94M-$86M-$163,766-$31M
Gross MarginGross profit ÷ Revenue+28.9%+28.0%+22.8%+32.5%+62.7%
Operating MarginEBIT ÷ Revenue-10.2%-2.7%-24.1%-1.5%+13.3%
Net MarginNet income ÷ Revenue+6.5%-2.5%-111.0%-4.9%+11.2%
FCF MarginFCF ÷ Revenue-13.0%-8.1%-29.3%-0.1%-8.7%
Rev. Growth (YoY)Latest quarter vs prior year+48.6%+3.0%+20.9%+2.0%+6.8%
EPS Growth (YoY)Latest quarter vs prior year+175.0%+70.7%+83.8%-100.0%-94.5%
ACB leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

Evenly matched — OGI and TLRY each lead in 2 of 4 comparable metrics.
MetricOGI logoOGIOrganigram Global…TLRY logoTLRYTilray Brands, In…CGC logoCGCCanopy Growth Cor…CRON logoCRONCronos Group Inc.ACB logoACBAurora Cannabis I…
Market CapShares × price$186M$660M$122M$981M$195M
Enterprise ValueMkt cap + debt − cash$172M$806M$293M$190M$136M
Trailing P/EPrice ÷ TTM EPS-13.45x-0.17x-0.28x164.21x
Forward P/EPrice ÷ next-FY EPS est.9.82x34.27x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple6.73x
Price / SalesMarket cap ÷ Revenue1.37x0.59x0.62x5.07x0.77x
Price / BookPrice ÷ Book value/share0.69x0.25x0.34x0.90x0.43x
Price / FCFMarket cap ÷ FCF
Evenly matched — OGI and TLRY each lead in 2 of 4 comparable metrics.

Profitability & Efficiency

ACB leads this category, winning 6 of 9 comparable metrics.

ACB delivers a 7.2% return on equity — every $100 of shareholder capital generates $7 in annual profit, vs $-137 for TLRY. CRON carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to CGC's 0.72x. On the Piotroski fundamental quality scale (0–9), ACB scores 7/9 vs OGI's 2/9, reflecting strong financial health.

MetricOGI logoOGIOrganigram Global…TLRY logoTLRYTilray Brands, In…CGC logoCGCCanopy Growth Cor…CRON logoCRONCronos Group Inc.ACB logoACBAurora Cannabis I…
ROE (TTM)Return on equity+4.9%-136.5%-43.1%-0.9%+7.2%
ROA (TTM)Return on assets+3.4%-100.6%-29.5%-0.8%+5.2%
ROICReturn on invested capital-17.8%-66.2%-10.2%-0.8%+0.7%
ROCEReturn on capital employed-16.0%-78.1%-12.4%-0.3%+0.7%
Piotroski ScoreFundamental quality 0–924567
Debt / EquityFinancial leverage0.03x0.22x0.72x0.00x0.17x
Net DebtTotal debt minus cash-$19M$147M$235M-$790M-$80M
Cash & Equiv.Liquid assets$28M$304M$114M$792M$184M
Total DebtShort + long-term debt$9M$451M$348M$2M$104M
Interest CoverageEBIT ÷ Interest expense-89.43x-7.79x6.27x
ACB leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

TLRY leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in TLRY five years ago would be worth $3,498 today (with dividends reinvested), compared to $45 for CGC. Over the past 12 months, TLRY leads with a +1209.3% total return vs ACB's -25.3%. The 3-year compound annual growth rate (CAGR) favors TLRY at 26.7% vs CGC's -55.9% — a key indicator of consistent wealth creation.

MetricOGI logoOGIOrganigram Global…TLRY logoTLRYTilray Brands, In…CGC logoCGCCanopy Growth Cor…CRON logoCRONCronos Group Inc.ACB logoACBAurora Cannabis I…
YTD ReturnYear-to-date-20.2%-41.8%-5.0%-4.8%-21.0%
1-Year ReturnPast 12 months+23.2%+1209.3%-12.4%+38.9%-25.3%
3-Year ReturnCumulative with dividends-34.3%+103.6%-91.4%+29.1%-47.2%
5-Year ReturnCumulative with dividends-87.5%-65.0%-99.6%-66.6%-96.1%
10-Year ReturnCumulative with dividends-95.6%-74.7%-94.3%+1457.6%-92.0%
CAGR (3Y)Annualised 3-year return-13.1%+26.7%-55.9%+8.9%-19.2%
TLRY leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

CRON leads this category, winning 2 of 2 comparable metrics.

CRON is the less volatile stock with a 0.98 beta — it tends to amplify market swings less than TLRY's 2.03 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CRON currently trades 74.9% from its 52-week high vs TLRY's 36.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricOGI logoOGIOrganigram Global…TLRY logoTLRYTilray Brands, In…CGC logoCGCCanopy Growth Cor…CRON logoCRONCronos Group Inc.ACB logoACBAurora Cannabis I…
Beta (5Y)Sensitivity to S&P 5001.33x2.03x1.90x0.98x1.81x
52-Week HighHighest price in past year$2.24$15.70$2.38$3.43$6.67
52-Week LowLowest price in past year$1.10$0.35$0.84$1.84$3.07
% of 52W HighCurrent price vs 52-week peak+61.6%+36.1%+47.5%+74.9%+51.4%
RSI (14)Momentum oscillator 0–10046.837.952.949.352.2
Avg Volume (50D)Average daily shares traded632K4.7M10.4M1.4M979K
CRON leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: OGI as "Buy", TLRY as "Hold", CGC as "Hold", CRON as "Hold", ACB as "Hold". Consensus price targets imply 1180.5% upside for CGC (target: $14) vs -10.5% for CRON (target: $2).

MetricOGI logoOGIOrganigram Global…TLRY logoTLRYTilray Brands, In…CGC logoCGCCanopy Growth Cor…CRON logoCRONCronos Group Inc.ACB logoACBAurora Cannabis I…
Analyst RatingConsensus buy/hold/sellBuyHoldHoldHoldHold
Price TargetConsensus 12-month target$10.00$14.47$2.30$5.92
# AnalystsCovering analysts520261514
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%0.0%+1.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

ACB leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). TLRY leads in 1 (Total Returns). 1 tied.

Best OverallAurora Cannabis Inc. (ACB)Leads 2 of 6 categories
Loading custom metrics...

OGI vs TLRY vs CGC vs CRON vs ACB: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is OGI or TLRY or CGC or CRON or ACB a better buy right now?

For growth investors, Cronos Group Inc.

(CRON) is the stronger pick with 64. 4% revenue growth year-over-year, versus -9. 5% for Canopy Growth Corporation (CGC). Aurora Cannabis Inc. (ACB) offers the better valuation at 164. 2x trailing P/E, making it the more compelling value choice. Analysts rate Organigram Global Inc. (OGI) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — OGI or TLRY or CGC or CRON or ACB?

On forward P/E, Organigram Global Inc.

is actually cheaper at 9. 8x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — OGI or TLRY or CGC or CRON or ACB?

Over the past 5 years, Tilray Brands, Inc.

(TLRY) delivered a total return of -65. 0%, compared to -99. 6% for Canopy Growth Corporation (CGC). Over 10 years, the gap is even starker: CRON returned +1458% versus OGI's -95. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — OGI or TLRY or CGC or CRON or ACB?

By beta (market sensitivity over 5 years), Cronos Group Inc.

(CRON) is the lower-risk stock at 0. 98β versus Tilray Brands, Inc. 's 2. 03β — meaning TLRY is approximately 107% more volatile than CRON relative to the S&P 500. On balance sheet safety, Cronos Group Inc. (CRON) carries a lower debt/equity ratio of 0% versus 72% for Canopy Growth Corporation — giving it more financial flexibility in a downturn.

05

Which is growing faster — OGI or TLRY or CGC or CRON or ACB?

By revenue growth (latest reported year), Cronos Group Inc.

(CRON) is pulling ahead at 64. 4% versus -9. 5% for Canopy Growth Corporation (CGC). On earnings-per-share growth, the picture is similar: Aurora Cannabis Inc. grew EPS 102. 2% year-over-year, compared to -651. 7% for Tilray Brands, Inc.. Over a 3-year CAGR, CRON leads at 30. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — OGI or TLRY or CGC or CRON or ACB?

Aurora Cannabis Inc.

(ACB) is the more profitable company, earning 0. 5% net margin versus -266. 3% for Tilray Brands, Inc. — meaning it keeps 0. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACB leads at 1. 4% versus -277. 9% for TLRY. At the gross margin level — before operating expenses — ACB leads at 54. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is OGI or TLRY or CGC or CRON or ACB more undervalued right now?

On forward earnings alone, Organigram Global Inc.

(OGI) trades at 9. 8x forward P/E versus 34. 3x for Cronos Group Inc. — 24. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CGC: 1180. 5% to $14. 47.

08

Which pays a better dividend — OGI or TLRY or CGC or CRON or ACB?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is OGI or TLRY or CGC or CRON or ACB better for a retirement portfolio?

For long-horizon retirement investors, Cronos Group Inc.

(CRON) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 98), +1458% 10Y return). Tilray Brands, Inc. (TLRY) carries a higher beta of 2. 03 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CRON: +1458%, TLRY: -74. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between OGI and TLRY and CGC and CRON and ACB?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: OGI is a small-cap high-growth stock; TLRY is a small-cap quality compounder stock; CGC is a small-cap quality compounder stock; CRON is a small-cap high-growth stock; ACB is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

OGI

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 24%
  • Net Margin > 5%
Run This Screen
Stocks Like

TLRY

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 16%
Run This Screen
Stocks Like

CGC

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 10%
  • Gross Margin > 13%
Run This Screen
Stocks Like

CRON

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 100%
  • Gross Margin > 19%
Run This Screen
Stocks Like

ACB

Steady Growth Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 6%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform OGI and TLRY and CGC and CRON and ACB on the metrics below

Revenue Growth>
%
(OGI: 48.6% · TLRY: 3.0%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.